The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
I'm hoping a new CEO will be in place before the July AGM. Things may pick up around then when they try to turn this into an actual business. A few quick wins (f*ck Ken and TRX off immediately, CLX partnered, lab sold, biobank sold and positive news on other compounds). Suzy is bound to leave some open goals for the new CEO to take advantage of.
Until we see a TR-1 from the main shareholder advising he is reducing his stake I don't think VAL can be written off just yet.
Cheers Bob, saved me a job putting the f**kwit right.
Let's not forget the ValiRx mission statement to 'ACCELERATE the development of treatments in cancer and women’s health to improve patient lives'.
The harsh reality is that they are accelerating absolutely f**k all.
I'm guessing the further CLX formulations haven't gone that well, considering the quarter referenced is now long gone.
From RNS dated 15th December 2023:
'CLX001 was placed in the single asset subsidiary company, Cytolytix Limited ("Cytolytix") in Q4 2022, and has undergone a programme of formulation development during H1 2023. The peptide active ingredient requires a nanoformulation to ensure that the peptide stabilised within the therapeutic agent and is delivered to cancer cells at appropriate levels.
The formulation development remains challenging, with further formulations being proposed and undergoing testing during the quarter.'
Nice to see Adrian confirmed as a NED. A decent holding, which puts other current members of the BOD to shame.
The already dreadful news flow was never going to get any better, once the search for a new CEO was announced.
We just have to wear it for the time being.
I'd have thought Cox and Lampshire would've wanted to get some news out though. As things stand they'll still be targets even though the requisition was pulled. Their time will come.
Not sure if the US markets were closed yesterday but I don't think there was a single trade in EUDA.
Thought these were going back to 60p? ;-)
ValiRx 'ACCELERATES the development of treatments in cancer and women’s health to improve patient lives', I'll have you know! 🤣
If no material news is released before the new CEO is announced; The SH's whom made the requisition, can feel thoroughly vindicated in what must have been a difficult decision.
The current BOD have failed to convert ANY income generating opportunities and have left the company in a somewhat precarious position whereby another fundraise now seems inevitable.
If only there was a novel drug out there, which could make a difference to a fraction of these people!
https://www.theguardian.com/society/2024/apr/04/prostate-cancer-cases-worldwide-diagnoses-deaths-2040-study
'Diagnoses are projected to increase from 1.4m a year in 2020 to 2.9m by 2040, which will mean about 330 men being told they have the disease every hour'
201 on the shelf for over three years because of money. Well done guys.
Two years out of date and counting.
Https://www.telegraph.co.uk/business/2023/10/31/ftse-100-markets-news-mortgages-latest/
I should probably be a bit clearer, for those narrow-minded of us, whom are unable to grasp my point...............a sign of things to come for AIM.
RedX delisting from AIM. Maybe a sign of things to come.
Getting back to VAL.....from RNS dated 15th December 2023:
'CLX001 was placed in the single asset subsidiary company, Cytolytix Limited ("Cytolytix") in Q4 2022, and has undergone a programme of formulation development during H1 2023. The peptide active ingredient requires a nanoformulation to ensure that the peptide stabilised within the therapeutic agent and is delivered to cancer cells at appropriate levels.
The formulation development remains challenging, with further formulations being proposed and undergoing testing during the quarter.'
If they are making progress inline with their expectations, we should have some news on the successful formulation of CLX shortly. The lab is doing f*ck all else to generate any income and this is closest to being sold; So I would expect this activity to top of the 'urgent' pile.
Have a day off watching then ;-)
2p. Wow. It's nearly $1.8 now. ;-)
That Theorem website gets worse with every development. They can't even update Dodgy Ken's profile pic with one that's in focus. Absolutely bobbins.
First time for everything I suppose ;-)
Pj, I'm of the opinion AIM has been f*cked by too many lifestyle CEO's pumping their SP's with any old dross over the last five years or so.
The market only responds to tangible metrics these days. Anything vaguely sounding like jam tomorrow is dismissed out of hand.
CLX and the new evaluations might make it incredibly appealing to a dynamic, commercially astute individual whom has the ambition to make a name for themselves in the Biotech sector.
Are you sure you have you decimal point in the correct place for your pence/vol. dung ratio? ;-)
Hopefully, the new CEO will have a better awareness of the need to generate short term income. I'm sure that message will be relayed loud and clear during the recruitment process.